The Industrial Technology Research Institute (ITRI), Taiwan, has signed a Memorandum of Understanding (MoU) with Merck, announcing the establishment of Taiwan-Merck Biopharma R&D & Training Collaboration Program at ITRI Guangfu Innovation Campus in Hsinchu. 

This project is expected to strengthen Taiwan’s biopharma sector by combining the R&D resources from ITRI with key technologies and advanced manufacturing processes from Merck to cultivate high-end professionals in Taiwan. The collaboration aims to enhance Taiwan’s biopharma production competence, expand the global market share of its biopharma industry, and create new business opportunities in precision medicine.

Dr. Chii-Wann Lin, Vice President of ITRI and General Director of its Biomedical Technology and Device Research Laboratories, explained that this collaboration includes two stages, and the Taiwan-Merck Biopharma R&D & Training Collaboration Program is only the beginning of this joint program.

In addition to introducing world-leading drug manufacturing and purifying technologies and high-efficiency mass production processes, the program will bring in validation and verification methods that meet the standards of international, European, and US regulations.